Richard Fishel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Richard Fishel has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Beiyuan Liang
Department of Cancer Biology and Genetics, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio
14 shared publications - Chunjie Li
Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio
14 shared publications - Evan H. Zhang
Department of Cancer Biology and Genetics, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio
14 shared publications - Hayden Storts
Department of Cancer Biology and Genetics, The Ohio State University, Columbus, Ohio, USA
14 shared publications - Hazel Claybon
Department of Cancer Biology and Genetics, James Comprehensive Cancer Center, Wexner Medical Center, The Ohio State University, Columbus, Ohio
14 shared publications - Jenna Wilson
Department of Cancer Biology and Genetics, James Comprehensive Cancer Center, Wexner Medical Center, The Ohio State University, Columbus, Ohio
14 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by Springer Nature in Nature Communications
An accessible Python framework for real-time magnetic tweezers microscope control and image processing
- 4 November 2026
- Published by Springer Nature in Nature Communications
Open AccessAn accessible Python framework for real-time magnetic tweezers microscope control and image processing
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer
Supplemental figure 5 and legend
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer
Supplemental figure 5 and legend
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer
Supplemental figure 3 and legend
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer
Supplemental figure 3 and legend
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer
Supplemental figure 2 and legend
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer
Supplemental figure 2 and legend
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer
Supplemental figure 1 and legend
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer
Supplemental figure 1 and legend
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer
Supplemental figure 4 and legend
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer
Supplemental figure 4 and legend
- Open Access
An Accessible Python Framework for Real-Time Magnetic Tweezers Microscope Control and Image Processing
Magnetic tweezers are a popular biophysical instrument for manipulating and measuring single molecules. Most groups rely on custom-built setups tailored to specific experiments, making it challenging to implement and share software. Typically, image acquisition and hardware control are automated via LabVIEW, while real-time video processing is implemented in C++/CUDA libraries. Live processing can eliminate the need to store raw video, enabling high throughput, fast acquisition rates, and simplified experimental workflows. However, no open-source general-purpose software framework currently unifies these capabilities for magnetic tweezers experiments. Here, we introduce MagTrack and MagScope open-source Python-based tools designed to fill this gap. MagTrack is an image-processing library that efficiently determines bead-positions from magnetic-tweezers videos using CPU and/or GPU computation. MagScope is a comprehensive software framework offering a graphical user interface, real-time hardware control, data acquisition, and video processing. It is built on a multiprocessing architecture for responsive, high-throughput computation. Together, MagTrack and MagScope offer a fully customizable, end-to-end, open-source Python alternative to proprietary or fragmented systems, enabling laboratories to adapt and extend the framework according to their experimental needs.
Open AccessAn Accessible Python Framework for Real-Time Magnetic Tweezers Microscope Control and Image Processing
Magnetic tweezers are a popular biophysical instrument for manipulating and measuring single molecules. Most groups rely on custom-built setups tailored to specific experiments, making it challenging to implement and share software. Typically, image acquisition and hardware control are automated via LabVIEW, while real-time video processing is implemented in C++/CUDA libraries. Live processing can eliminate the need to store raw video, enabling high throughput, fast acquisition rates, and simplified experimental workflows. However, no open-source general-purpose software framework currently unifies these capabilities for magnetic tweezers experiments. Here, we introduce MagTrack and MagScope open-source Python-based tools designed to fill this gap. MagTrack is an image-processing library that efficiently determines bead-positions from magnetic-tweezers videos using CPU and/or GPU computation. MagScope is a comprehensive software framework offering a graphical user interface, real-time hardware control, data acquisition, and video processing. It is built on a multiprocessing architecture for responsive, high-throughput computation. Together, MagTrack and MagScope offer a fully customizable, end-to-end, open-source Python alternative to proprietary or fragmented systems, enabling laboratories to adapt and extend the framework according to their experimental needs.
- Open Access
- 2 January 2025
- Published by American Association for Cancer Research (AACR)
Data from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer
Colorectal cancer is the second leading cause of cancer mortality in the United States. Although immune checkpoint blockade therapies including anti-PD-1/PD-L1 have been successful in treating a subset of patients with colorectal cancer, the response rates remain low. We have found that riluzole, a well-tolerated FDA-approved oral medicine for treating amyotrophic lateral sclerosis, increased intratumoral CD8+ T cells and suppressed tumor growth of colon cancer cells in syngeneic immune–competent mice. Riluzole-mediated tumor suppression was dependent on the presence of CD8+ T cells. Riluzole activates the cytosolic DNA sensing cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) pathway in colon cancer cells, resulting in increased expression of IFNβ and IFNβ-regulated genes including CXCL10. Inhibition of ataxia telangiectasia mutated (ATM), but not ATM-related, resulted in a synergistic increase in IFNβ expression, suggesting that riluzole induces ATM-mediated damage response that contributes to cGAS/STING activation. Depletion of cGAS or STING significantly attenuated riluzole-induced expression of IFNβ and CXCL10 as well as increase of intratumoral CD8+ T cells and suppression of tumor growth. These results indicate that riluzole-mediated tumor infiltration of CD8+ T cells and attenuation of tumor growth is dependent on tumor cell–intrinsic STING activation. To determine whether riluzole treatment primes the tumor microenvironment for immune checkpoint modulation, riluzole was combined with anti-PD-1 treatment. This combination showed greater efficacy than either single agent and strongly suppressed tumor growth in vivo. Taken together, our studies indicate that riluzole activates cGAS/STING-mediated innate immune responses, which might be exploited to sensitize colorectal tumors to anti-PD-1/PD-L1 therapies.
- 2 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer
Colorectal cancer is the second leading cause of cancer mortality in the United States. Although immune checkpoint blockade therapies including anti-PD-1/PD-L1 have been successful in treating a subset of patients with colorectal cancer, the response rates remain low. We have found that riluzole, a well-tolerated FDA-approved oral medicine for treating amyotrophic lateral sclerosis, increased intratumoral CD8+ T cells and suppressed tumor growth of colon cancer cells in syngeneic immune–competent mice. Riluzole-mediated tumor suppression was dependent on the presence of CD8+ T cells. Riluzole activates the cytosolic DNA sensing cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) pathway in colon cancer cells, resulting in increased expression of IFNβ and IFNβ-regulated genes including CXCL10. Inhibition of ataxia telangiectasia mutated (ATM), but not ATM-related, resulted in a synergistic increase in IFNβ expression, suggesting that riluzole induces ATM-mediated damage response that contributes to cGAS/STING activation. Depletion of cGAS or STING significantly attenuated riluzole-induced expression of IFNβ and CXCL10 as well as increase of intratumoral CD8+ T cells and suppression of tumor growth. These results indicate that riluzole-mediated tumor infiltration of CD8+ T cells and attenuation of tumor growth is dependent on tumor cell–intrinsic STING activation. To determine whether riluzole treatment primes the tumor microenvironment for immune checkpoint modulation, riluzole was combined with anti-PD-1 treatment. This combination showed greater efficacy than either single agent and strongly suppressed tumor growth in vivo. Taken together, our studies indicate that riluzole activates cGAS/STING-mediated innate immune responses, which might be exploited to sensitize colorectal tumors to anti-PD-1/PD-L1 therapies.